Patients must be enrolled within 1 year after diagnosis
Patients currently enrolled in other clinical trials testing a therapeutic intervention
Patients enrolled in any other clinical studies the investigator believes to be in conflict with this investigation
Subjects currently enrolled in any other clinical protocol or investigational trial that involves administration of experimental therapy and/or therapeutic devices, or investigational drug
Patients may not be enrolled on any other therapeutic trial for which they are receiving an anti-tumor therapy
EXPANDED ACCESS COHORT: Participants must be currently enrolled to DFCI protocol number 13-506 or discontinued from protocol 13-506 solely because the study agents were no longer available via protocol 13-506
Note: Patients may be enrolled more than once (e.g., for a new tumor)
Patient is currently enrolled in any other clinical protocol or investigational trial that involves administration of experimental therapy and/or therapeutic devices, or investigational drug
Currently enrolled in a clinical study.
Patient is receiving or plans to receive other investigational therapy and/or is enrolled or plans to enroll in a separate clinical study.
Subjects in concurrent studies can only be enrolled with permission from Medtronic. Please contact Medtronic's study manager to determine if the subject can be enrolled in both studies.
Currently enrolled in another interventional study.
Currently enrolled in another investigational therapy protocol for AML.
Consent for tumor biopsies (for patients enrolled in stage 1 only) and blood draws for research purposes (for all patients)
Previously enrolled in the present study
If you are pregnant, you will not be enrolled on this study
Currently enrolled in another clinical trial.
Patients who are simultaneously enrolled in any other treatment study
Patients with evidence of another malignancy, exclusive of a skin cancer that requires only local treatment, should not be enrolled on this protocol
PART 2: Meeting criteria for 1st phase as above, at time of initiation of JAK inhibitor, including ability to understand and willingness to sign a written informed consent; patients arriving to our institution for transplant and not enrolled in Part 1 may still be enrolled in Part 2 if Part 1 criteria met; these patients will have Part 1 endpoints transcribed from medical records
Shares the same address as a currently enrolled participant
Patients who are simultaneously enrolled in any other treatment study
Patients with evidence of another malignancy, exclusive of a skin cancer that requires only local treatment, should not be enrolled on this protocol
Patients with evidence of another malignancy, exclusive of a skin cancer that requires only local treatment, should not be enrolled on this protocol
Currently enrolled and receiving treatment in an Incyte-sponsored clinical study of ruxolitinib that has completed or been terminated.
Subjects cannot be simultaneously enrolled on other treatment studies
Previously enrolled in this study.
Previous or concurrent cancer that is distinct from tumor for which the patient is enrolled in study, with exceptions
Currently enrolled in a Valor-sponsored IGN002 study
Participation in other investigational studies while enrolled on this trial.
RENAL & BLADDER: Currently enrolled in another interventional study
Enrolled in another clinical trial with a targeted endpoint of treating the patient’s cancer (observational trials are acceptable)
Only patients with tumors that score positive in the in vitro organoid bio-assay will be enrolled in the clinical trial; patients with tumors that score negative in this bio-assay will be considered screening failures and will not be enrolled in the clinical trial
Patients must be enrolled on ALTE07C1 prior to enrollment on ACNS1123; patients must be enrolled within 31 days of definitive diagnostic surgery (day 0) or clinical diagnosis
FOR PATIENTS IN STAGE 2 (ENROLLED PATIENT #18 AND BEYOND)
Subjects who have recently been enrolled in other experimental clinical trials of\n             investigational agents
Patients must be enrolled within 56 weeks following completion of therapy
Patients who are currently receiving chemotherapy, radiation therapy or are enrolled in another therapeutic clinical trial
If patient goes on to have an open thoracotomy as part of surgical treatment they will not be enrolled
Patients enrolled on another therapeutic study
Patients must be enrolled between 8 to 20 weeks post OLT
Subject is currently enrolled in any other clinical protocol or investigational trial that involves administration of experimental therapy and/or therapeutic devices, or investigational drug.
Hepatitis B + patients may be enrolled at the discretion of the investigator
Currently enrolled in study CCL09101E, or YM387-II-02, or successfully completed 24 weeks of study GS-US-352-1672
Are currently enrolled in another clinical trial.
Organ function requirements are not required for enrolled patients who are stage I, PFH and will not be receiving chemotherapy
For patients with EOC enrolled in the single agent expansion stage:
Patients who are currently enrolled on another clinical trial
Patients enrolled in other clinical trials must have received their last treatment at least 6 weeks prior to enrollment
Currently enrolled in other professional tobacco cessation therapeutic intervention
Patients who are simultaneously enrolled in other treatment studies
Are currently enrolled or discontinued less than 14 days from another clinical trial
Patients who are enrolled in other symptom management or symptom clinical trials
Exclusion criteria below (*) apply only to patients who are enrolled AFTER completing 3 to 6 cycles of first-line chemotherapy; exclusion criteria (*) DO NOT APPLY to patients who are enrolled prior to completing 3 to 6 cycles of first-line chemotherapy; these patients can be enrolled but ultimately MAY not be treated with radiation therapy/SBRT; this is dependent on their restaging imaging after the completion of chemotherapy
Patients who are enrolled in a national/international cooperative group trials
Patients must have been enrolled, or agree to consent to the companion genomic profiling study MSKCC IRB# 12-245; results must be available before starting treatment on protocol
Be currently enrolled in another investigational treatment protocol
Patients who have received prior treatment with antiCTLA-4 may be enrolled, provided the following requirements are met:
Subject is enrolled in any other clinical protocol or investigational trial with an interventional agent or assessments that may interfere with study procedures.
Previously or currently enrolled in Protocol No. TPI-287-17
Patient is enrolled in any other therapeutic clinical protocol or investigational trial
Patients enrolled must, in the Investigator's judgment, be healthy enough to stay on the clinical trial for three months.
Patient is enrolled in any other therapeutic clinical protocol or investigational trial
Be currently enrolled in another investigational protocol
Patients must have been enrolled, or agree to consent to the companion genomic profiling study MSKCC IRB# 12-245
Currently enrolled in any other clinical protocol or investigational trial that involves administration of experimental therapy and/or therapeutic devices.
Patients enrolled into phase Ib may be enrolled with evaluable disease only. Patients enrolled into the phase II expansion must have at least one measurable lesion as defined by RECIST 1.1 criteria for solid tumors.
Donor must not be currently enrolled on another investigational agent study.
Currently enrolled in another interventional study
Patients currently enrolled in another study; concurrent enrollment in another study is prohibited expect for the control arm which can be used for other protocols with HRQOL endpoints with similar instruments
Be planning to start yoga on their own during the time they are enrolled in the study
Another household member enrolled in the study
Currently already enrolled on the TrueNTH website
Patients enrolled on another clinical trial which prohibits the use of pre-phase therapy or any of its components
Enrolled on a phase I trial
Patient is currently enrolled in hospice
101 Subject was previously enrolled in Study 20062004.
Patients enrolled in other CGA studies will not be excluded
Patients currently enrolled onto therapeutic cancer clinical trial(s) involving non-standard cancer drugs
Participants may be enrolled on other treatment-based clinical trials but may not be enrolled on any other weight loss trials
Patients currently enrolled on Children's Oncology Group (COG) study ACCL0934 are not eligible until they have completed the infection observation period of that study
Patients previously enrolled on this trial are ineligible
Patients previously enrolled on the trial are not eligible; therefore, patients with AL who were on study during intensive chemotherapy are not eligible to be enrolled during the HSCT
Patients currently enrolled on the ACCL1034 study are not eligible until they have completed the 90 day observation period of that study
Currently enrolled in a physical therapy course
Patients must be enrolled in a Phase 1 clinical trial and be within 2 weeks of starting the experimental therapy or intervention
ONCOLOGIST: Have a patient panel that will allow for >= 6 eligible patients to be enrolled in the study
Patients enrolled on other supportive care intervention trials
Subjects must be already enrolled in P.R.O.G.E.C.T observational registry (HSC #12614)
Individuals who are enrolled on oral chemotherapy clinical trials will also be excluded
Two discretionary enrollment criteria include:\r\n* Patients with ductal breast carcinoma in situ (DCIS) may be enrolled into the study if they are eligible for and considering either mastectomy or BCS with radiation\r\n* Patients taking neoadjuvant chemotherapy may be enrolled into the study if they are eligible for and considering either mastectomy or BCS
Patients who are enrolled in other clinical trials that have symptom management as primary outcome
Has another family member already enrolled in ICCAN (as determined by patient report)
Patients who are enrolled in other symptom management clinical trials
Patients who are enrolled in another symptom management trial
Are enrolled in any other cancer prevention/outreach related study
No patients will be enrolled that require sedation for the MRI
enrolled in a competing study; and
BETA/USABILITY TESTING: Will have been enrolled for year prior to the mammogram at Group Health
Another household member being enrolled in the study.
Individuals enrolled in or who plan to enroll in a clinical intervention trial; there must be a 30-day period between completing a previous study and enrolling in this study; the principal investigator will have the option to consider an exception for patients on drugs of interest for the purpose of this study
Currently enrolled in an ‘in-person’ cessation program
Patients with pT3a disease who lack one of the above criteria, and who refuse adjuvant radiation, may also be enrolled
Pregnant women are excluded from this study; patients enrolled in the study must be able to undergo intensive RT plus or minus chemotherapy
Another household member enrolled in the study
Currently enrolled at Salish Kootenai College
Currently enrolled on an interventional investigational study
Patients enrolled on another investigational trial for oral mucositis prevention
Another household member enrolled in the study
Participants who are already enrolled in a conflicting investigational trial
Enrolled in study part #1
Enrolled in any other clinical studies the investigator believes to be in conflict with this investigation
Patients who are not enrolled in the OCSP
Urinalysis abnormalities will not preclude the patient from being enrolled and studied
Patients preparing to receive therapy for pancreas cancer, including patients enrolled in HRPO# 201201124 or other clinical trials, are eligible
Patients may not be concurrently enrolled to another clinical trial for the treatment of cancer; co-enrollment to biospecimen studies is allowed; patients may be enrolled to other clinical trials after completing all of the baseline interventions and measures
Enrolled in hospice
Currently enrolled in protocol 2014-0712 (PCS study)
Patients enrolled in any other clinical studies the investigator believes to be in conflict with this investigation.